---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006800"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T13:14:37.687366+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences completes Phase 3 enrollment for simufilam; Q3 net loss $25.7M

## Summary
- Enrollment completed: 1,929 patients randomized across two Phase 3 trials of simufilam for Alzheimer's.
- Top-line results expected year-end 2024 (52-week trial) and mid-2025 (76-week trial).
- Cash and equivalents $142.4M at Sept 30, 2023; no debt.
- Q3 net loss $25.7M ($0.61/sh) vs $20.3M ($0.51/sh) in Q3 2022, driven by higher clinical costs.
- Interim MRI safety data suggests simufilam not associated with ARIA; DSMB recommends continuation.

## SEC filing metadata
- accession: 0001171843-23-006800
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184323006800/0001171843-23-006800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184323006800/f8k_110723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006800
- JSON: https://secwatch.observer/filing/0001171843-23-006800.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006800.txt

## Key facts
- Earnings Releases
  FILANA THERAPEUTICS, INC. reported the third quarter ended September 30, 2023 results: net income $25.7 million, or $0.61 per share, EPS $0.61 per share.
  - Period: the third quarter ended September 30, 2023
  - Net income: $25.7 million, or $0.61 per share
  - EPS: $0.61 per share
  - Result: reported results
  source text: Net loss was $25.7 million, or $0.61 per share. This compares to a net loss of $20.3 million, or $0.51 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000117184323006800/0001171843-23-006800-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.